Phenol

Phenol

SCHEMBL15955879

O=CC(Cl)(Cl)Cl.Oc1ccccc1.Oc1ccccc1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
GLA P06280 1/20 0.55
CA3 P07451 1/20 0.55
CA4 P22748 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
ESR1 P03372 5/20 0.43
ESR2 Q92731 4/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP3A4 P08684 1/20 0.43
MMP3 P08254 1/20 0.40
BCL2L1 Q07817 1/20 0.40
CES2 O00748 1/20 0.39
CYP1A2 P05177 1/20 0.39
ALDH5A1 P51649 1/20 0.39
ABAT P80404 1/20 0.39
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenol SCHEMBL28211059 1.00 TDP1 (0.55) TDP1CA12CA1CA2GLA
Phenol SCHEMBL11329973 0.98 TDP1 (0.52) TDP1CA12CA1CA2GLA
Phenol SCHEMBL27614600 0.81 TDP1 (0.65) TDP1CA12CA1CA2GLA
Phenol SCHEMBL28182274 0.81 TDP1 (0.65) TDP1CA12CA1CA2GLA
Phenol SCHEMBL9509973 0.81 CA12 (0.73) TDP1CA12CA1CA2GLA
Phenol SCHEMBL662758 0.78 TDP1 (0.69) TDP1CA12CA1CA2GLA
Phenol SCHEMBL30534252 0.78 TDP1 (0.69) TDP1CA12CA1CA2GLA
Phenol SCHEMBL16735107 0.78 TDP1 (0.69) TDP1CA12CA1CA2GLA
Phenol SCHEMBL5799389 0.78 TDP1 (0.69) TDP1CA12CA1CA2GLA
Phenol SCHEMBL29391610 0.78 TDP1 (0.69) TDP1CA12CA1CA2GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170233357-A1 PHENOLIC EPOXY COMPOUNDS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2017-08-17 US claimed
US-20170233522-A1 PHENOLIC EPOXY COMPOUNDS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2017-08-17 US claimed
US-20160009672-A1 PHENOLIC EPOXY COMPOUNDS CRESTLINE DIRECT FINANCE, L.P. 2016-01-14 US claimed
WO-2014126625-A1 MULTI-FUNCTIONAL ACRYLATES EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-08-21 WO claimed
WO-2014126626-A1 PHENOLIC EPOXY COMPOUNDS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-08-21 WO claimed
US-10106494-B2 Gemini surfactant and their use EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2018-10-23 US disclosed
US-9890130-B2 Phenolic epoxy compounds EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2018-02-13 US disclosed
US-9834522-B2 Multi-functional acrylates EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2017-12-05 US disclosed
US-20170233522-A1 PHENOLIC EPOXY COMPOUNDS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2017-08-17 US disclosed
US-20170233357-A1 PHENOLIC EPOXY COMPOUNDS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2017-08-17 US disclosed
US-20160368863-A1 NOVEL GEMINI SURFACTANT AND THEIR USE EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2016-12-22 US disclosed
EP-3077364-A1 NOVEL GEMINI SURFACTANTS AND THEIR USE Empire Technology Development LLC (US) 2016-10-12 EP disclosed
US-20160009672-A1 PHENOLIC EPOXY COMPOUNDS CRESTLINE DIRECT FINANCE, L.P. 2016-01-14 US disclosed
US-20150376149-A1 MULTI-FUNCTIONAL ACRYLATES CRESTLINE DIRECT FINANCE, L.P. 2015-12-31 US disclosed
WO-2015084304-A1 NOVEL GEMINI SURFACTANTS AND THEIR USE EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2015-06-11 WO disclosed
WO-2014126626-A1 PHENOLIC EPOXY COMPOUNDS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-08-21 WO disclosed
WO-2014126625-A1 MULTI-FUNCTIONAL ACRYLATES EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106494-B2 Gemini surfactant and their use GEMIN4, GMNN, GEMIN5 TDP1 2566/4885CA12 3385/4885CA1 3323/4885
US-20170233522-A1 PHENOLIC EPOXY COMPOUNDS ESR1, PTGES, COMT TDP1 3394/4885CA12 3759/4885CA1 4199/4885
US-20160009672-A1 PHENOLIC EPOXY COMPOUNDS COMT, ESR1, EED TDP1 3085/4885CA12 4071/4885CA1 4391/4885
US-20170233357-A1 PHENOLIC EPOXY COMPOUNDS COMT, ESR1, EED TDP1 3085/4885CA12 4071/4885CA1 4391/4885
US-20150376149-A1 MULTI-FUNCTIONAL ACRYLATES AAAS, PNMT, PFAS TDP1 594/4885CA12 4036/4885CA1 4232/4885
US-20160368863-A1 NOVEL GEMINI SURFACTANT AND THEIR USE GEMIN4, GEMIN5, GMNN TDP1 2473/4885CA12 3650/4885CA1 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.